Clovis Oncology Valuation
| CLVSDelisted Stock | USD 0.09 0.02 24.00% |
Clovis Oncology seems to be overvalued based on Macroaxis valuation methodology. Our model approximates the value of Clovis Oncology from analyzing the firm fundamentals such as Operating Margin of (1.55) %, shares outstanding of 144.96 M, and Return On Asset of -0.3 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Clovis Oncology's price fluctuation is very steady at this time. Calculation of the real value of Clovis Oncology is based on 3 months time horizon. Increasing Clovis Oncology's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Clovis stock is determined by what a typical buyer is willing to pay for full or partial control of Clovis Oncology. Since Clovis Oncology is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Clovis Stock. However, Clovis Oncology's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.093 | Real 0.0884 | Hype 0.09 |
The intrinsic value of Clovis Oncology's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Clovis Oncology's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Clovis Oncology helps investors to forecast how Clovis stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Clovis Oncology more accurately as focusing exclusively on Clovis Oncology's fundamentals will not take into account other important factors: Clovis Oncology Total Value Analysis
Clovis Oncology is currently anticipated to have valuation of 651.32 M with market capitalization of 11.77 M, debt of 436.77 M, and cash on hands of 94.58 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Clovis Oncology fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
651.32 M | 11.77 M | 436.77 M | 94.58 M |
Clovis Oncology Investor Information
About 26.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings To Growth (PEG) ratio of 0.13. Clovis Oncology recorded a loss per share of 2.08. The entity had not issued any dividends in recent years. Based on the key measurements obtained from Clovis Oncology's financial statements, Clovis Oncology is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.Clovis Oncology Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Clovis Oncology has an asset utilization ratio of 31.46 percent. This implies that the Company is making $0.31 for each dollar of assets. An increasing asset utilization means that Clovis Oncology is more efficient with each dollar of assets it utilizes for everyday operations.Clovis Oncology Ownership Allocation
Clovis Oncology holds a total of 144.96 Million outstanding shares. Almost 72.68 percent of Clovis Oncology outstanding shares are held by general public with 1.43 (percent) owned by insiders and only 25.89 % by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Clovis Oncology Profitability Analysis
The company reported the previous year's revenue of 148.76 M. Net Loss for the year was (264.52 M) with profit before overhead, payroll, taxes, and interest of 115.3 M.About Clovis Oncology Valuation
The delisted stock valuation mechanism determines Clovis Oncology's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Clovis Oncology based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Clovis Oncology. We calculate exposure to Clovis Oncology's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Clovis Oncology's related companies.Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Clovis Oncology, Inc. was incorporated in 2009 and is headquartered in Boulder, Colorado. Clovis Oncology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 413 people.
Clovis Oncology Growth Indicators
Investing in growth stocks can be very risky. If the company such as Clovis Oncology does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 121.2 M | |
| Retained Earnings | -2.9 B | |
| Retained Earnings Total Equity | -2.9 B |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Other Consideration for investing in Clovis Stock
If you are still planning to invest in Clovis Oncology check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Clovis Oncology's history and understand the potential risks before investing.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |